Researchers at St. Jude developed an anti-CD7 chimeric antigen receptor (CD7 CAR) to use for treating hematologic cancers expressing the CD7 gene, which include lymphoblastic T-cell leukemia and lymphomas. The majority of T-cells, approximately 90%, express CD7 and are removed before transduction. The CD7 CAR is introduced into the remaining subset of T cells that do not naturally express CD7.
chimeric antigen receptor, gene therapy vector, anti-CD7-CAR, T-cell malignancies
Granted Patents or Published Applications
Granted Patents or Published Applications Patent pending
Related Scientific References
Please contact us if you are interested in licensing this technology. Contact: email@example.com.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.